WO2014127232A3 - Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy - Google Patents

Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy Download PDF

Info

Publication number
WO2014127232A3
WO2014127232A3 PCT/US2014/016477 US2014016477W WO2014127232A3 WO 2014127232 A3 WO2014127232 A3 WO 2014127232A3 US 2014016477 W US2014016477 W US 2014016477W WO 2014127232 A3 WO2014127232 A3 WO 2014127232A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment site
methods
therapeutic cells
subject
need
Prior art date
Application number
PCT/US2014/016477
Other languages
French (fr)
Other versions
WO2014127232A2 (en
Inventor
Patrick Ching-Ho HSIEH
Chia-Yun Lai
Original Assignee
Dcb-Usa Llc
National Cheng Kung University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dcb-Usa Llc, National Cheng Kung University filed Critical Dcb-Usa Llc
Priority to EP14751247.9A priority Critical patent/EP2964237A4/en
Priority to CN201480008940.3A priority patent/CN105228632A/en
Priority to US14/767,774 priority patent/US20150374741A1/en
Publication of WO2014127232A2 publication Critical patent/WO2014127232A2/en
Publication of WO2014127232A3 publication Critical patent/WO2014127232A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells

Abstract

Disclosed herein are methods for maintaining a population of therapeutic cells administered to a treatment site in a subject in need of cell therapy for a period of time. The methods include administering a therapeutically-effective amount of therapeutic cells and an effective amount of a biodegradable material to the treatment site. The biodegradable material includes a hyaluronan compound and has an in vivo degradation profile similar to that of a hyaluronic acid having a molecular weight of 20 kDa to 2,000 kDa.
PCT/US2014/016477 2013-02-15 2014-02-14 Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy WO2014127232A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP14751247.9A EP2964237A4 (en) 2013-02-15 2014-02-14 Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
CN201480008940.3A CN105228632A (en) 2013-02-15 2014-02-14 A kind of method maintaining the treatment position needing to accept in the individual body of cell therapy in order to a group to be treated cell
US14/767,774 US20150374741A1 (en) 2013-02-15 2014-02-14 Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361765075P 2013-02-15 2013-02-15
US61/765,075 2013-02-15

Publications (2)

Publication Number Publication Date
WO2014127232A2 WO2014127232A2 (en) 2014-08-21
WO2014127232A3 true WO2014127232A3 (en) 2015-10-29

Family

ID=51354685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/016477 WO2014127232A2 (en) 2013-02-15 2014-02-14 Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy

Country Status (3)

Country Link
EP (1) EP2964237A4 (en)
CN (1) CN105228632A (en)
WO (1) WO2014127232A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016243612A1 (en) * 2015-03-31 2017-10-12 The University Of North Carolina At Chapel Hill Delivery vehicles for stem cells and uses thereof
US20170151416A1 (en) * 2015-12-01 2017-06-01 Invivo Therapeutics Corporation Methods and Systems for Delivery of a Trail of a Therapeutic Substance into an Anatomical Space
US10676634B2 (en) * 2018-09-05 2020-06-09 Swimc Llc Modified latent crosslinker in polymeric systems
IT201800020722A1 (en) * 2018-12-21 2020-06-21 Assunta Borzacchiello Biomaterial and its use in the treatment of lung diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011072399A1 (en) * 2009-12-18 2011-06-23 The Governing Council Of The University Of Toronto Injectable polymer composition for use as a cell delivery vehicle
US20120156176A1 (en) * 2009-04-30 2012-06-21 University of Pittsburgh-Of the Commonwealth Syste Thermoresponsive, biodegradable, elastomeric material and uses therefor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482231B1 (en) * 1995-11-20 2002-11-19 Giovanni Abatangelo Biological material for the repair of connective tissue defects comprising mesenchymal stem cells and hyaluronic acid derivative
US8137688B2 (en) * 2003-01-10 2012-03-20 The Cleveland Clinic Foundation Hydroxyphenyl cross-linked macromolecular network and applications thereof
JP2007535486A (en) * 2003-05-07 2007-12-06 ラ ホーヤ インスティチュート フォー モレキュラー メディシン Method for promoting functional recovery of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid
CA2633954A1 (en) * 2005-12-14 2007-06-21 Anika Therapeutics, Inc. Meniscal implant of hyaluronic acid derivatives for treatment of meniscal defects
EP2132303A2 (en) * 2007-03-06 2009-12-16 University Of North Carolina At Chapel Hill Complexes of hyaluronans, other matrix components, hormones and growth factors for maintenance, expansion and/or differentiation of cells
US20140227235A1 (en) * 2011-07-13 2014-08-14 Cha Bio & Diostech Co., Ltd. Cartilage cell treatment comprising collagen, hyaluronic acid derivative, and stem cell derived from mammal umbilical cord

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120156176A1 (en) * 2009-04-30 2012-06-21 University of Pittsburgh-Of the Commonwealth Syste Thermoresponsive, biodegradable, elastomeric material and uses therefor
WO2011072399A1 (en) * 2009-12-18 2011-06-23 The Governing Council Of The University Of Toronto Injectable polymer composition for use as a cell delivery vehicle

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIAN ET AL.: "Enhanced MSC chondrogenesis following delivery of TGF-beta3 from alginate microspheres within hyaluronic acid hydrogels in vitro and in vivo", BIOMATERIALS, vol. 32, no. 27, pages 6425 - 6434, XP028254231, ISSN: 0142-9612 *
BURDICK ET AL.: "Controlled degradation and mechanical behavior of photopolymerized hyaluronic acid networks", BIOMACROMOLECULES, vol. 6, no. 1, January 2005 (2005-01-01), pages 386 - 391, XP008069736, ISSN: 1525-7797 *
LEI ET AL.: "The spreading, migration and proliferation of mouse mesenchymal stem cells cultured inside hyaluronic acid hydrogels", BIOMATERIALS, vol. 32, no. 1, pages 39 - 47, XP027493687, ISSN: 0142-9612 *
See also references of EP2964237A4 *

Also Published As

Publication number Publication date
EP2964237A4 (en) 2016-11-30
EP2964237A2 (en) 2016-01-13
CN105228632A (en) 2016-01-06
WO2014127232A2 (en) 2014-08-21

Similar Documents

Publication Publication Date Title
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
MY171929A (en) Corticosteroids for the treatment of joint pain
WO2017044894A3 (en) Cartilage-homing peptides
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
PE20150223A1 (en) ANTIBODIES ENHANCED ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND THE USES OF THEM
MX346224B (en) Compostions and methods for treating chronic inflammation and inflammatory diseases.
MX348420B (en) Treatment of the adverse side-effects associated with administration of an anti-hyaluronan agent.
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
EP3818991A3 (en) Compositions and methods for treating diseases
IN2012DN02645A (en)
EP3792280A3 (en) Anti-blys antibody
WO2016210376A3 (en) Therapeutic peptides and methods of use thereof
MA40057A (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
TN2014000236A1 (en) Use of chemically modified heparin derivates in sickle cell disease
MX2018008658A (en) Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria.
AR088585A1 (en) A MEDICINAL PRODUCT TO TREAT THE PREVIOUS EYE DISEASE
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2014160216A3 (en) Dual targeting anticancer agents
WO2014127232A3 (en) Methods for maintaining population of therapeutic cells in treatment site of subject in need of cell therapy
EP2818172A4 (en) Tlr4 agent, tissue homeostasis agent, hepatocyte growth factor inducer, tissue repairing agent, and sirtuin inducer having hyaluronic acid fragments as active ingredients thereof
WO2014153385A3 (en) Methods of treating metabolic disorders
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
WO2013156488A3 (en) Optimised subcutaneous therapeutic agents
BR112014011744A2 (en) sustainable action formulation of cyclosporine form 2
FR2978665B1 (en) ANTISEPTIC COMPOSITION

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480008940.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14751247

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2014751247

Country of ref document: EP